Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L. Crombie(Dana-Farber Cancer Institute), Michael Dickinson(The University of Melbourne), Jeremy S. Abramson(Massachusetts General Hospital), Rajat Bannerji(Rutgers, The State University of New Jersey), Sonali M. Smith(University of Chicago), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Benjamin M. Parsons(Gundersen Health System), Joshua Brody(New York University), Ayed O. Ayed(Florida Cancer Specialists & Research Institute), Jeffrey P. Sharman(Willamette Valley Cancer Institute and Research Center), Victoria Nachar(Michigan Medicine), Alex F. Herrera(City of Hope), Catherine Thiéblemont(Université Paris Cité), Krish Patel, Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Marshall McKenna(Rutgers, The State University of New Jersey), Yasmin Karimi(Michigan Medicine), Philippe Armand(Harvard University), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Tycel Phillips(Michigan Medicine), Martin Hutchings(University of Copenhagen), Brad S. Kahl(UW Health University Hospital), J. Weiss(University of Michigan), Nancy L. Bartlett(Washington University in St. Louis), Lihua E. Budde(City Of Hope National Medical Center), Matthew A. Lunning(University of Nebraska Medical Center), Nirav N. Shah(Medical College of Wisconsin), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Tara Graff(Blood Cancer UK), Jane Osterson(Blood Cancer UK), Manali Kamdar(University of Colorado Cancer Center), Rénata Ursu(Assistance Publique – Hôpitaux de Paris), Ian W. Flinn(Tennessee Oncology)
Cited by 132
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k